MIH
AZN icon

Meitav Investment House’s AstraZeneca AZN Stock Holding History

Meitav Investment House’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,000
Closed -$341K – 342
2017
Q4 		$341K Buy
+5,000
New +$337K 0.02% 175

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Meitav Investment House's AZN Position: Q1 2026 in Review

Meitav Investment House sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 10,020 shares — an estimated $1.84M sold.

Meitav Investment House first reported a position in AZN in Q1 2018 and held it in 27 quarters. The position peaked at $15.6M in Q4 2024. 1,381 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Meitav Investment House reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Meitav Investment House sold 10,020 AstraZeneca shares in Q1 2026, an estimated $1.84M.
  • Meitav Investment House first reported a position in AstraZeneca in Q1 2018 and held it in 27 quarters.
  • Meitav Investment House's AstraZeneca position peaked at $15.6M in Q4 2024.
  • 1,381 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Meitav Investment House's 13F filing for Q1 2026, filed 29 Apr 2026.